You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

164 Results
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Feb 2026
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
Sep 2022
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
Sep 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant, Curative, Palliative
Aug 2021
Drug
Other Name(s): Keytruda®
Feb 2026
Drug
Other Name(s): Vectibix®
Jan 2025
Drug
Other Name(s): Polivy™
Updated
Mar 2026
Drug
Other Name(s): Taxol®
Nov 2024
Drug
Other Name(s): Caelyx®
Sep 2025
Drug
Other Name(s): Neulasta®, Lapelga®, Fulphila™; Ziextenzo®; Nyvepria™, Niopeg®, Pexegra™
Sep 2025
Drug
Other Name(s): Votrient®
Dec 2025
Drug
Jan 2026

Pages